Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03398824 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Metformin for Patients With Fanconi Anemia
A Phase 2 study, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT03398824 is a Phase 2 study that has completed, run by Boston Children's Hospital. The registered enrollment target is 15 participants.
The verdict
NCT03398824, a Phase 2 study, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a single institution, open-label, single arm pilot study of Metformin in patients with Fanconi Anemia (FA) and cytopenias with the primary endpoint of hematologic response. This study will also assess safety, tolerability, and the biologic effects of Metformin in patients with FA.
Interventions
- DRUG metformin HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-03-29 |
| Est. Completion | 2020-10-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03398824
The ClinicalTrials.gov registry entry for NCT03398824 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which metformin HCl is the first listed.
NCT03398824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03398824 about?
NCT03398824 is a clinical study titled "Pilot Study of Metformin for Patients With Fanconi Anemia". This is a single institution, open-label, single arm pilot study of Metformin in patients with Fanconi Anemia (FA) and cytopenias with the primary endpoint of hematologic response. This study will also assess safety, tolerability, and the biologic effects of Metformin in patients with FA.
What is the current status of trial NCT03398824?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2018-03-29. Estimated completion is 2020-10-09.
What interventions are being tested in trial NCT03398824?
The interventions under investigation include: metformin HCl (DRUG).
Who is sponsoring clinical trial NCT03398824?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.